Activation of Adriamycin by the pH-dependent formaldehyde-releasing prodrug hexamethylenetetramine

Molecular Cancer Therapeutics

Volumn 2, Issue 2, 2003, Pages 189-198

  Swift, Lonnie P ^a   Cutts, Suzanne M ^a   Rephaeli, Ada ^b   Nudelman, Abraham ^c   Phillips, Don R ^a  

^a LA TROBE UNIVERSITY   (Australia)

^b TEL AVIV UNIVERSITY   (Israel)

^c BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; DOXORUBICIN; FORMALDEHYDE; METHENAMINE; PRODRUG;

ARTICLE; BIOSYNTHESIS; BIOTRANSFORMATION; CELL CULTURE; DNA ADDUCT; GENETICS; HUMAN; METABOLISM; NEUROBLASTOMA; PH;

ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; DNA ADDUCTS; DNA, NEOPLASM; DOXORUBICIN; FORMALDEHYDE; HUMANS; HYDROGEN-ION CONCENTRATION; METHENAMINE; NEUROBLASTOMA; PRODRUGS; TUMOR CELLS, CULTURED;

EID: 0041766275     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Supported by the Australian Research Council (D. R. P. and S. M. C.), La Trobe University Postgraduate Scholarship (to L. P. S.), The Marcus Center for Pharmaceutical and Medicinal Chemistry, and the Bronia and Samuel Hacker Fund for Scientific Instrumentation at Bar Ilan University (A. N.).
2. DeVita, V. T., Hellman, S., and Rosenberg, S. A. Cancer, Principles and Practice of Oncology, 5th ed. Philadelphia: Lippincott-Raven, 1997.
3. Pratt, W. B., Ruddon, R. W., Ensiminger, W. D., and Maybaum, J. The Anticancer Drugs, 2nd ed., pp. 1-165. New York: Oxford University Press, 1994.
4. Taatjes, D. J., Gaudiano, G., Resing, K., and Koch, T. H. Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs Adriamycin and daunomycin. J. Med. Chem., 40: 1276-1286, 1997. (Pubitemid 27175107)
5. Doroshow, J. H. Role of reactive-oxygen metabolism in cardiac toxicity of anthracycline antibiotics. In: W. Priebe (ed.), Anthracycline Antibiotics: New Analogues, Methods of Delivery, and Mechanisms of Action, pp. 259-267. Washington, DC: American Chemical Society, 1995.
6. Berman, E., and McBride, M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood, 79: 3267-3273, 1992.
7. Gewirtz, D. A., Randolph, J. K., Chawla, J., Orr, M. S., and Fornari, F. A. Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line. Cancer Chemother. Pharmacol., 41: 361-369, 1998. (Pubitemid 28095751)
8. Fornari, F. A., Jr., Jarvis, D. W., Grant, S., Orr, M. S., Randolph, J. K., White, F. K., and Gewirtz, D. A. Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin. Biochem. Pharmacol., 51: 931-940, 1996. (Pubitemid 26109490)
9. Binaschi, M., Capranico, G., Dal Bo, L., and Zunino, F. Relationship between lethal effects and topoisomerase II-mediated double-strand DNA breaks produced by anthracyclines with different sequence specificity. Mol. Pharmacol., 51: 1053-1059, 1997. (Pubitemid 27249139)
10. Pommier, Y. DNA topoisomerases and their inhibition by anthracyclines. In: W. Priebe (ed.), Anthracycline Antibiotics: New Analogues, Methods of Delivery, and Mechanisms of Action, Vol. 574, pp. 183-203. Washington, DC: American Chemical Society, 1995.
11. Capranico, G., Zunino, F., Kohn, K. W., and Pommier, Y. Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationships with DNA binding affinity and cytotoxicity. Biochemistry, 29: 562-569, 1990. (Pubitemid 20037665)
12. Cullinane, C., van Rosmalen, A., and Phillips, D. R. Does Adriamycin induce interstrand cross-links in DNA? Biochemistry, 33: 4632-4638, 1994. (Pubitemid 24145112)
13. Taatjes, D. J., Gaudiano, G., and Koch, T. H. Production of formaldehyde and DNA-Adriamycin or DNA-daunomycin adducts, initiated through redox chemistry of dithiothreitol/iron, xanthine oxidase/NADH/iron, or glutathione/iron. Chem. Res. Toxicol., 10: 953-961, 1997. (Pubitemid 27418010)
14. Zeman, S. M., Phillips, D. R., and Crothers, D. M. Characterization of covalent Adriamycin-DNA adducts. Proc. Natl. Acad. Sci. USA, 95: 11561-11565, 1998. (Pubitemid 28460454)
15. Phillips, D. R., and Cullinane, C. Adriamycin. In: T. E. Creighton (ed.), The Encyclopedia of Molecular Biology, Vol. 1, pp. 68-72. New York: John Wiley and Sons, 1999.
16. Wang, J., Gao, Y. G., Liaw, C. Y., and Li, Y. K. Formaldehyde crosslinks daunorubicin and DNA efficiently: HPLC and X-ray diffraction studies. Biochemistry, 30: 3812-3815, 1991.
17. Wang, J. Y-T., Chao, M., and Wang, A. H-J. Adducts of DNA and anthracycline antibiotics: structures, interactions, and activities. In: W. Priebe (ed.), Anthracycline Antibiotics: New Analogues, Methods of Delivery and Mechanisms of Action, Vol. 574, pp. 168-182. Washington, DC: American Chemical Society, 1995.
18. Fenick, D. J., Taatjes, D. J., and Koch, T. H. Doxoform and daunoform: anthracycline-formaldehyde conjugates toxic to resistant tumor cells. J. Med. Chem., 40: 2452-2461, 1997. (Pubitemid 27347009)
19. Leng, F. F., Savkur, R., Fokt, I., Przewloka, T., Priebe, W., and Chaires, J. B. Base specific and regioselective chemical cross-linking of daunorubicin to DNA. J. Am. Chem. Soc., 118: 4731-4738, 1996. (Pubitemid 26186543)
20. Cutts, S. M., Parker, B. S., Swift, L. P., Kimura, K. I., and Phillips, D. R. Structural requirements for the formation of anthracycline-DNA adducts. Anticancer Drug Des., 15: 373-386, 2000. (Pubitemid 32441352)
21. Niitsu, N., Kasukabe, T., Yokoyama, A., Okabe-Kado, J., Yamamoto-Yamaguchi, Y., Umeda, M., and Honma, Y. Anticancer derivative of butyric acid (pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity. Mol. Pharmacol., 58: 27-36, 2000. (Pubitemid 30452525)
22. Taatjes, D. J., Fenick, D. J., and Koch, T. H. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines. Chem. Res. Toxicol., 12: 588-596, 1999. (Pubitemid 29354741)
23. Cutts, S. M., Rephaeli, A., Nudelman, A., Hmelnitsky, I., and Phillips, D. R. Molecular basis for the synergistic interaction of Adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cancer Res., 61: 8194-8202, 2001. (Pubitemid 33091612)
24. Dreyfors, J. M., Jones, S. B., and Sayed, Y. Hexamethylenetetramine: a review. Am. Ind. Hyg. Assoc. J., 50: 579-585, 1989. (Pubitemid 19269246)
25. Hamilton-Miller, J. M., and Brumfitt, W. Methenamine and its salts as urinary tract antiseptics: variables affecting the antibacterial activity of formaldehyde, mandelic acid, and hippuric acid in vitro. Invest. Urol., 4: 287-291, 1977. (Pubitemid 8046715)
26. Ragimov, C. R. The efficacy of preparations with antioxidant action in the combined treatment of phlegmons of the maxillofacial area. Stomatologiya (Mosc.), 71: 35-37, 1992.
27. Cronberg, S., Welin, C. O., Henriksson, L., Hellsten, S., Persson, K. M., and Stenberg, P. Prevention of recurrent acute cystitis by methenamine hippurate: double blind controlled crossover long term study. Br. Med. J. Clin. Res., 294: 1507-1508, 1987. (Pubitemid 17108384)
28. Iskandarova, G. T. Hygienic rationale for maximum permissible concentration of hexamethylenetetramine salt of 2-chloroethylphosphonic acid. Gig. Sanit., 10: 14-17, 1993.
29. Christensen, H. E., Fairchild, E. J., and Lewis, R. J. Suspected Carcinogens: A Subfile of the NIOSH Registry of Toxic Effects of Chemical Substances, 2nd ed., p. 123. Cincinnati, Ohio: National Institute for Occupational Safety and Health, Center for Disease Control, 1976.
30. Rephaeli, A., Rabizadeh, E., Aviram, A., Shaklai, M., Ruse, M., and Nudelman, A. Derivatives of butyric acid as potential anti-neoplastic agents. Int. J. Cancer, 49: 66-72, 1991.
31. Warburg, O. On the origin of cancer cells. Science (Wash. DC), 123: 309-314, 1956.
32. Griffiths, J. R. Are cancer cells acidic? Br. J. Cancer, 64: 425-427, 1991.
33. Negendank, W. Studies of human tumors by MRS: a review. NMR Biomed., 5: 303-324, 1992.
34. McCoy, C. L., Parkins, C. S., Chaplin, D. J., Griffiths, J. R., Rodrigues, L. M., and Stubbs, M. The effect of blood flow modification on intra- and extracellular pH measured by 31P magnetic resonance spectroscopy in murine tumours. Br. J. Cancer, 72: 905-911, 1995.
35. 31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate. Am. J. Physiol., 267: C195-C203, 1994.
36. Raghunand, N., He, X., van Sluis, R., Mahoney, B., Baggett, B., Taylor, C. W., Paine-Murrieta, G., Roe, D., Bhujwalla, Z. M., and Gillies, R. J. Enhancement of chemotherapy by manipulation of tumour pH. Br. J. Cancer, 80: 1005-1011, 1999. (Pubitemid 29233921)
37. Zhen, W., Evans, M. K., Haggerty, C. M., and Bohr, V. A. Deficient gene specific repair of cisplatin-induced lesions in Xeroderma pigmentosum and Fanconi's anemia cell lines. Carcinogenesis (Lond.), 14: 919-924, 1993. (Pubitemid 23169148)
38. Cullinane, C., and Phillips, D. R. Thermal stability of DNA adducts induced by cyanomorpholinoadriamycin in vitro. Nucleic Acids Res., 21: 1857-1862, 1993. (Pubitemid 23178903)
39. Maxam, A. M., and Gilbert, W. A new method for sequencing DNA. Proc. Natl. Acad. Sci. USA, 74: 560-564, 1977. (Pubitemid 8038842)
40. Barltrop, J. A., Owen, T. C. 5-(3-carboxymethoxyphenyl)-2-(4,5- dimethylthiazolyl)-3-(4-sulfophenyl)tetrazolium, inner salt (MTS) and related analogs of 3-(4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide (MTT) reducing to purple water-soluble formazans as cell-viability indicators. Bioorg. Med. Chem. Lett., 1: 611-614, 1991.
41. Cory, A. H., Owen, T. C., Barltrop, J. A., and Cory, J. G. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun., 3: 207-212, 1991.
42. Cullinane, C., Cutts, S. M., Panousis, C., and Phillips, D. R. Interstrand cross-linking by Adriamycin in nuclear and mitochondrial DNA of MCF-7 cells. Nucleic Acids Res., 28: 1019-1025, 2000. (Pubitemid 30085330)
43. Vos, J. M. DNA Repair: A Laboratory Manual of Research Procedures, Vol. 3, pp. 367-398. New York: Marcel Dekker, 1988.
44. Cullinane, C., and Phillips, D. R. Induction of stable transcriptional blockage sites by Adriamycin: GpC specificity of apparent Adriamycin-DNA adducts and dependence on iron(III) ions. Biochemistry, 29: 5638-5646, 1990. (Pubitemid 20202293)
45. Walker, J. F. Formaldehyde, 3rd ed., pp. 511-551. New York: Reinhold, 1964.
46. Gollamudi, R., Straughn, A., and Meyer, M. Urinary excretion of methenamine and formaldehyde: evaluation of 10 methenamine products in humans. J. Pharm. Sci., 70: 596-599, 1981. (Pubitemid 11035284)
47. Goodman, L. S., Hardman, J. G., Limbird, L. E., and Gilman, A. G. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed., p. 1184. New York: McGraw-Hill, 2001.
48. Cutts, S. M., and Phillips, D. R. Use of oligonucleotides to define the site of interstrand cross-links induced by Adriamycin. Nucleic Acids Res., 23: 2450-2456, 1995.
49. Strom, J. G., Jr., and Jun. H. W. Separation and quantitation of methenamine in urine by ion-pair extraction. J. Pharm. Sci., 75: 416-420, 1986.